TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01904526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
Study: NCT01474473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot
Description: The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Nonremovable, Windowed, Fiberglass Cast Boot
Description: The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days
Study: NCT00098137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan
Study: NCT04012593

Intervention type: BEHAVIORAL
Intervention: Diary
Study: NCT00952068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid® OAD 200mg
Description: 1 Tramadol Contramid® OAD 200mg tablet daily.
Study: NCT01659593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procog
Description: 3 to 5 people group program
Study: NCT03683485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long duration EPBD
Description: An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long duration EPBD
Description: An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EST
Description: After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EST
Description: After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
Study: NCT04212091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm
Study: NCT01659593

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01453088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.
Study: NCT04212091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: Administered via IV infusion or SC infusion, depending on the arm
Study: NCT02248753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological cardioversion - Amiodarone
Study: NCT00791102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP-1001 nasal spray
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Study: NCT04212091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered via IV infusion or SC infusion, depending on the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered via IV infusion or SC infusion, depending on the arm
Study: NCT02132299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
Study: NCT01503632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive intervention program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Correlative studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance Monitoring
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02132299

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
Study: NCT01093742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01503632

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01093742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01503632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Receive usual standard of care
Study: NCT01093742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02519348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Study: NCT00791102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ASP-1001
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Study: NCT01984853

Intervention type: OTHER
Intervention: OBSERVATIONAL REGISTRY
Study: NCT04397614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Assessments
Description: Daily symptom tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Assessments
Description: Daily symptom tracker
Study: NCT04480723

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood samples will be taken and analyzed to evaluate the presence of PH.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI will be performed to evaluate the presence of PH.
Study: NCT02397681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Function Testing
Description: Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
Study: NCT03729765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion
Description: The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
Study: NCT03555708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
Study: NCT02519348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
Study: NCT03609112

Intervention type: OTHER
Intervention: The WISC-V
Description: The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).

Intervention type: OTHER
Intervention: The WISC-V
Description: The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).

Intervention type: OTHER
Intervention: The WISC-V
Description: The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).
Study: NCT05473949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Description: Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Study: NCT05473949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Description: use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Study: NCT03609112

Intervention type: OTHER
Intervention: The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort)
Description: The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort) which assesses fatigue in everyday life.
Study: NCT02126579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.
Study: NCT03298009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Description: 2-week intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 2-week intervention

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET imaging
Description: 1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: 1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
Study: NCT01802372

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHO CVD risk assessment package
Description: Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Insurance only
Description: Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
Study: NCT01374542

Intervention type: PROCEDURE
Intervention: Respiratory endoscopy
Description: Bronchoscopy, thoracoscopy, endobronchial ultrasound
Study: NCT03088267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphetamine extended-release oral suspension, 2.5 mg/mL
Description: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amphetamine extended-release oral suspension, 2.5 mg/mL
Description: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo extended-release oral suspension
Description: 6, 7 or 8 mL PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo extended-release oral suspension
Description: 6, 7 or 8 mL PO
Study: NCT02126579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.
Study: NCT01508429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 placebo tablets (resembling misoprostol) administered sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 800mcg misoprostol (4 200mcg tablets administered sublingually)
Study: NCT01782066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEN-ACYW135 reduced-dose intradermal administration
Description: Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEN-ACYW135 reduced-dose intradermal administration
Description: Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
Study: NCT04278118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo hypofractionated proton or photon radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies